Immunotherapy with MVA-BN^sup ?^-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells

• Published in: Cancer immunology, immunotherapy Vol. 61; no. 1; p. 19
• Main Authors: Mandl, Stefanie J, Rountree, Ryan B, Dalpozzo, Katie, Do, Lisa, Lombardo, John R, Schoonmaker, Peter L, Dirmeier, Ulrike, Steigerwald, Robin, Giffon, Thierry, Laus, Reiner, Delcayre, Alain
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Nature B.V 01.01.2012
• Subjects: Breast cancer; Clinical trials; Immunotherapy; Lungs; Lymphocytes; Metastasis; Proteins; Smallpox; Tetanus; Tumors; Vaccines; Turkey; Ankara Turkey; Germany

MVA-BN^sup ®^-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN^sup ®^-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occu...